Accutar Biotechnology

aid: accutar-biotechnology
name: Accutar Biotechnology
description: 'Accutar Biotechnology Inc. is a clinical-stage biotechnology company headquartered in Cranbury, New Jersey,
  founded in 2015 and previously based in Brooklyn, New York, with operations in Shanghai. It applies deep learning to small-molecule
  drug discovery and runs its own oncology pipeline, including the AC0682 and AC0176 protein degraders in Phase 1 trials.
  Its computational platform is a set of in-house AI products used in its own preclinical workflow and offered to partners:
  ChemiRise (retrosynthesis), Orbital (neural-network docking), Virtual Screen, Intelligent-SAR, Chemi-Net (ADME prediction)
  and the PatentOne AI suite (InsightOne, GenusOne). Accutar publishes no developer program: no public API, developer portal,
  reference documentation, machine-readable specification or SDK exists on any host it operates. Access to the AI products
  is arranged by email enquiry for a trial or demo.'
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: none
  source:
  - security
  generated: '2026-11-06'
  method: derived
image: https://www.accutarbio.com/wp-content/themes/accutar/images/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/accutar-biotechnology/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-harvest-source-url: https://forgeglobal.com/accutar-biotechnology_stock/
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Artificial Intelligence
- Machine Learning
- Cheminformatics
- Oncology
- Life Sciences
- Health
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Artificial Intelligence
- Machine Learning
- Cheminformatics
- Oncology
- Life Sciences
- Health
- Machine-Learning
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/accutar-biotechnology-domain-security.yml
- type: Website
  url: https://www.accutarbio.com/
- type: Solutions
  url: https://www.accutarbio.com/products/
- type: Blog
  url: https://www.accutarbio.com/blog/
- type: BlogRSS
  url: https://www.accutarbio.com/feed/
- type: PressReleases
  url: https://www.accutarbio.com/news/
- type: Contact
  url: https://www.accutarbio.com/contact/
- type: Careers
  url: https://www.accutarbio.com/careers/
- type: LLMsTxt
  url: llms/accutar-biotechnology-llms.txt
- type: Plans
  url: plans/accutar-biotechnology-plans-pricing.yml
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 4
  pass: local-v3
x-coverage:
  state: none
  reason: no-developer-program
  detail: Accutar's AI products are offered only as end-user tools reached by emailing bd@accutarbio.com or demoinsightone@accutarbio.com
    for a demo — there is no developer section on accutarbio.com, api./docs./developer./app.accutarbio.com all fail to resolve
    in DNS, and the only machine-readable surface on the site is the stock WordPress /wp-json/ CMS endpoint, which is not
    an Accutar product.
  evidence:
  - url: https://www.accutarbio.com/products/
    status: 200
  - url: https://www.accutarbio.com/genusone/
    status: 200
  - url: https://www.accutarbio.com/openapi.json
    status: 404
  - url: https://www.accutarbio.com/llms.txt
    status: 404
  - url: https://www.accutarbio.com/.well-known/agent-card.json
    status: 404
  - url: https://www.accutarbio.com/.well-known/ae-control-probe
    status: 404
  checked: '2026-09-06'